المصدر: Zacks Investment Research
وكالة أنباء
الأسهم
أهمية متوسطة
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates
Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.
الرموز ذات الصلة
1
G
GYRE
GYRE
المصدر: Zacks Investment Research
زيارة المصدر